This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nomura, S. Articles by Hayashi, K. Search for Related Content PubMed PubMed Citation Articles by Nomura, S. Articles by Hayashi, K. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Elevation of Activated Platelet-Dependent Chemokines in Patients With Anti-CD20 Monoclonal Antibody (Rituximab)–Treated Non-Hodgkin's Lymphoma

Division of Hematology at Kishiwada City Hospital, Kishiwada, Osaka, shosaku-n{at}mbp.ocn.ne.jp

Kazuyoshi Ishii, MD

Division of Hematology at Kishiwada City Hospital, Kishiwada, Osaka

Yuka Kamitsuji, MD

Matsushita Memorial Hospital, Moriguchi Osaka

Nobuhiko Uoshima, MD

Matsushita Memorial Hospital, Moriguchi Osaka

Emiko Ishikawa, MD

Hoshigaoka Koseinennkinn Hospital, Hirakata Osaka, Japan

Hitoshi Kitayama, MD

Hoshigaoka Koseinennkinn Hospital, Hirakata Osaka, Japan

Kunio Hayashi, MD

Hoshigaoka Koseinennkinn Hospital, Hirakata Osaka, Japan

.ocn.ne.jp. This study measured and compared levels of some chemokines in patients with rituximab-treated non-Hodgkin lymphoma because they may participate in the mechanism of efficacy of rituximab in non-Hodgkin lymphoma patients. Monocytic chemotactant protein-1, RANTES (regulated on activation, normally T-cell expressed and secreted), eotaxin, interleukin-8, neutrophil-activating protein-78, stromal cell-derived factor-1, and growth-regulating oncogene- in patients with rituximab-treated non-Hodgkin lymphoma were measured by enzyme-linked immunosorbent assay. Levels of RANTES were higher in non-Hodgkin lymphoma patients than in controls. Levels of monocytic chemotactant protein-1, RANTES, and neutrophil-activating protein-78 were significantly elevated before and after chemotherapy with rituximab treatment. However, the level of stromal cell-derived factor-1 did not exhibit a significant change. Before to after chemotherapy without rituximab treatment, all chemokine levels did not exhibit significant changes. These findings suggest that activated platelet-dependent chemokines such as RANTES and neutrophil-activating protein-78 may modulate the efficacy of rituximab in antibody-dependent cellular cytotoxity.

Key Words: Rituximab • non-Hodgkin's lymphoma • chemokine

Clinical and Applied Thrombosis/Hemostasis, Vol. 13, No. 2, 206-212 (2007)
DOI: 10.1177/1076029606295583


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?